{"organizations": [], "uuid": "ea36e589bd199107119a079f76bafc5ebdcd6d5f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-merrimack-provides-business-update/brief-merrimack-provides-business-update-and-reports-2017-financial-results-idUSASC09RPQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T12:42:00.000+02:00", "replies_count": 0, "uuid": "ea36e589bd199107119a079f76bafc5ebdcd6d5f"}, "author": "", "url": "https://www.reuters.com/article/brief-merrimack-provides-business-update/brief-merrimack-provides-business-update-and-reports-2017-financial-results-idUSASC09RPQ", "ord_in_thread": 0, "title": "BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "merrimack pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "financial results reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 10:45 AM / in 10 minutes BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results Reuters Staff March 12 (Reuters) - Merrimack Pharmaceuticals Inc: * MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS * ‍EXPECTS THREE CLINICAL READOUTS IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES​ * ‍ANNOUNCED FORMATION OF A NEW SCIENTIFIC ADVISORY BOARD WITH EXPERTISE IN PRECISION ONCOLOGY​ * MERRIMACK PHARMACEUTICALS -‍ CLOSURE OF 2017 WITH $93.4 MILLION IN CASH, CASH EQUIVALENTS, EXTINGUISHMENT OF $60.8 MILLION OF CONVERTIBLE DEBT IN Q4​ * MERRIMACK PHARMACEUTICALS - CONTINUES TO BELIEVE THAT CASH & CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO H2 2019 * Q4 LOSS PER SHARE $0.89 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T12:42:00.000+02:00", "crawled": "2018-03-12T13:01:50.006+02:00", "highlightTitle": ""}